WuXi STA Pharma, the small molecule manufacturing subsidiary of China’s largest CRO, WuXi AppTec (SHA: 603259; HK: 2359), will collaborate with Switzerland’s BioLingus to provide sublingual delivery formulations. WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. BioLingus’ proprietary technology forms injected small molecule, peptide and protein drugs to be administered sublingually (orally under the tongue). WuXi STA offers process development and manufacturing services to global pharmas.
Source: China Biotoday
